Vitiligo Skin Transplantation (MKTP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00830713|
Recruitment Status : Completed
First Posted : January 28, 2009
Last Update Posted : September 6, 2012
|Condition or disease||Intervention/treatment||Phase|
|Vitiligo||Procedure: Melanocyte-keratinocyte transplantation procedure (MKTP)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||October 2011|
|Actual Study Completion Date :||October 2011|
Experimental: MKTP treatment
subject will undergo MKTP
Procedure: Melanocyte-keratinocyte transplantation procedure (MKTP)
skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
- effectiveness of MKTP in treating vitiligo [ Time Frame: 6 months ]Assessed by percent repigmentation (excellent= 100%-95%, good= 94%-65%, fair= 64%-25%, poor= 24%-0%).
- safety of MKTP in treating vitiligo [ Time Frame: 6 months ]Assessed by frequency of adverse events, including, scarring, infection, etc.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00830713
|United States, Michigan|
|Henry Ford Medical Center, New Center One|
|Detroit, Michigan, United States, 48202|
|Principal Investigator:||Iltefat H Hamzavi, MD||Henry Ford Health Systems Dermatology Department|